Sign in

    Xiaobin Gao

    Research Analyst at Barclays

    Xiaobin Gao is an analyst at Barclays specializing in healthcare and pharmaceuticals, with coverage including major companies such as Sanofi SA. Gao’s research focuses on equity analysis and has contributed to Barclays’ sector insights with targeted earnings call questions and investment guidance, demonstrating a strong foundation in life sciences. Previously, Gao was affiliated with Yale University as a researcher in cancer genetics and molecular diagnostics before moving to Barclays. Gao’s credentials include advanced academic training and sector-specific expertise, supporting a reputation for insightful healthcare equity analysis.

    Xiaobin Gao's questions to Sanofi (SNY) leadership

    Xiaobin Gao's questions to Sanofi (SNY) leadership • Q2 2024

    Question

    An analyst from Barclays, on behalf of Ms. Xiaobin Gao, asked about the development timeline for the COVID-19 and flu combination vaccine with Novavax. They also inquired about its prospects versus solo flu vaccines and the potential synergies with Sanofi's own mRNA flu vaccine candidate.

    Answer

    Thomas Triomphe, EVP of Vaccines, explained that while specific timelines are not yet public, they aim to begin clinical operations for the combination vaccine in 2024. He stressed the goal is to create a best-in-class product without compromising safety or efficacy. He added that their next-generation mRNA flu program is synergistic, as it aims to improve the standard of care, which is a different approach from competitors.

    Ask Fintool Equity Research AI